Renal Cancer-Drug Pipeline Analysis and Market Forecasts to 2016

Oct. 10, 2010 - PRLog -- "Renal Cancer-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global renal cancer market. The report identifies the key trends shaping and driving the global renal cancer market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global renal cancer sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis.

Scope
The scope of the report includes:
-Annualized global renal cancer disease market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include targeted therapies, EGFR, RAF inhibitors and LAK and NK cells enhancers.
-Analysis of the current and future market competition in the global renal cancer market. The key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Amgen Inc., and WILEX AG.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for future market associated with renal cancer.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global renal cancer market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global renal cancer market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global renal cancer market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Renal Cancer: Market Characterization 6
2.1 Renal Cancer Market Size 6
2.2 Renal Cancer Market Forecast and CAGR 6
2.3 Drivers and Barriers for Renal Cancer Market 7
2.3.1 Drivers for Renal Cancer Market 7
2.3.2 Barriers for Renal Cancer Market 8
2.4 Opportunity and Unmet Need 8
2.5 Key Takeaway 9
3 Renal Cancer Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in Renal Cancer Market 11
3.3.1 Avastin (bevacizumab) 11
3.3.2 Sutent (sunitinib malate) 12
3.3.3 Votrient (pazopanib) 13
3.3.4 Afinitor (everolimus) 14
3.3.5 Nexavar (sorafenib) 14
3.3.6 Torisel (temsirolimus) 15
3.4 Major Marketed Products Comparison in Renal Cancer Market 16
3.5 Key Takeaway 17
4 Renal Cancer Market: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 Renal Cancer Therapeutics-Promising Drugs Under Clinical Development 20
4.4 Molecule Profile for Promising Drugs under Clinical Development 20
4.4.1 Oncophage (vitespen) 20
4.4.2 Axitinib 21
4.4.3 TroVax 21
4.4.4 ANYARA 22
4.4.5 RENCAREX 22
4.5 Renal Cancer Therapeutics Market-Clinical Pipeline by Therapeutic Class 23
4.6 Renal Cancer Pipeline-Pipeline by Clinical Phases of Development 24
4.6.1 Renal Cancer Therapeutics-Regulatory Filed Clinical Pipeline 24
4.6.2 Renal Cancer Therapeutics-Phase III Clinical Pipeline 25
4.6.3 Renal Cancer Therapeutics-Phase II Clinical Pipeline 28
4.6.4 Renal Cancer Therapeutics-Phase I Clinical Pipeline 44
4.6.5 Renal Cancer Therapeutics-Preclinical Pipeline 48
4.6.6 Renal Cancer Therapeutics-Drug Discovery Pipeline 49
4.7 Key Takeaway 49
5 Global Renal Cancer: Implications for Future Market Competition 50
6 Global Renal Cancer Market: Future Players in the Renal Cancer Market 51
6.1 Introduction 51
6.2 F. Hoffmann-La Roche Ltd/Genentech, Inc. 51
6.2.1 Company Overview 51
6.2.2 Business Description 52
6.3 Pfizer Inc. 54
6.3.1 Company Overview 54
6.3.2 Business Description 55
6.4 Novartis AG 58
6.4.1 Company Overview 58
6.4.2 Business Description 58
6.5 Amgen Inc. 60
6.5.1 Company Overview 60
6.5.2 Business Description 60
6.6 WILEX AG 62
6.6.1 Company Overview 62
6.6.2 Business Description 62
7 Global Renal Cancer Market: Appendix 64
7.1 Definitions 64
7.2 Acronyms 64
7.3 Research Methodology 65
7.3.1 Coverage 65
7.3.2 Secondary Research 65
7.3.3 Forecasting 66
7.3.4 Primary Research 68
7.3.5 Expert Panels 69
7.4 Contact Us 69
7.5 Disclaimer 69
7.6 Sources 70

List of Tables
Table 1:  Global Renal Cancer Therapeutics Market, Revenue Forecasts ($ m), 2001-2009 7
Table 2:  Global Renal Cancer Therapeutics Market, Revenue Forecasts ($ m), 2010-2016 7
Table 3:  Major marketed products comparison in Renal Cancer Market, 2009 16
……

List of Figures
Figure 1:  Global Renal Cancer Therapeutics Market Forecast, 2001-2016 6
Figure 2:  Renal Cancer Therapeutics Market-Opportunity and Unmet Need, 2009 8
Figure 3:  Renal Cancer Therapeutics Market-Strategic Competitor Assessment, 2009 10
……

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.